<p><em>Mesoblast 有权在 2026 年 6 月 30 日前提取高达 1.25 亿美元</em></p>
<p><em>新融资不会影响 Mesoblast 的任何重要资产或知识产权</em></p>
<p>纽约，2025 年 12 月 29 日（GLOBE NEWSWIRE）-- Mesoblast Limited（纳斯达克：MESO；ASX：MSB），全球领先的用于治疗炎症疾病的同种异体细胞药物公司，今天宣布已全额偿还 Oaktree Capital Management, Inc.的现有高级担保贷款，并部分偿还 NovaQuest Capital Management LLC 的次级特许权使用费融资，通过从现有 Mesoblast 股东和董事 Dr. Gregory George 提供的新五年融资中提取 7500 万美元。第二笔高达 5000 万美元的融资可在 Mesoblast 的选择下，直到 2026 年 6 月 30 日提取。</p>
<p>新的信用额度年利率为 8.00%，相比 Mesoblast 当前的债务融资大幅降低，且有五年的仅付息期。最初提取的 7500 万美元在 NovaQuest 债务偿还之前是无担保的，最晚在 2026 年 7 月 8 日偿还后，整个新融资（最高可达 1.25 亿美元）将仅以 Temcell1 特许权使用费作为担保。</p>
<p>与现有融资相比，新融资的整体成本大幅降低，可以随时偿还而不产生提前还款或补偿费用，不包括退出费用，不影响 Mesoblast 的任何重要资产或知识产权，并且对额外的无担保债务或许可活动没有限制。Dr. George 将获得五年期的认股权证，可以以每股 21.51 美元的价格购买约 323,000 股美国存托股票（ADS），该价格比当前 30 天的加权平均价高出 15%，需经股东批准。</p>
<p>Mesoblast 首席执行官 Dr. Silviu Itescu 表示：“我们非常感谢我们最大的股东在今年的竞争过程中提供了最具商业吸引力的融资。这项融资大幅降低了公司的资本成本，并释放了我们所有主要资产，为战略合作伙伴关系和商业化提供了完全的灵活性。”</p>
<p><strong>关于 Mesoblast</strong></p>
<p>Mesoblast（公司）是开发同种异体（现成）细胞药物以治疗严重和危及生命的炎症疾病的全球领导者。公司专有的间充质谱系细胞治疗技术平台的疗法通过释放抗炎因子来应对严重炎症，抵消和调节免疫系统的多个效应臂，从而显著减少有害的炎症过程。</p>
<p>Mesoblast 的 Ryoncil®（remestemcel-L-rknd）用于治疗 2 个月及以上儿童患者的类固醇难治性急性移植物抗宿主病（SR-aGvHD），是 FDA 批准的首个间充质基质细胞（MSC）疗法。请参阅完整的处方信息，网址为 www.ryoncil.com。</p>
<p>Mesoblast 致力于基于其 remestemcel-L 和 rexlemestrocel-L 同种异体基质细胞技术平台开发针对不同适应症的额外细胞疗法。Ryoncil®正在开发用于包括成人 SR-aGvHD 和生物抵抗性炎症性肠病在内的其他炎症疾病。Rexlemestrocel-L 正在开发用于心力衰竭和慢性下背痛。公司已在日本、欧洲和中国建立了商业合作伙伴关系。</p>
<p><strong>关于 Mesoblast 的知识产权：</strong> Mesoblast 拥有强大而广泛的全球知识产权组合，拥有超过 1000 项已授予的专利或专利申请，涵盖间充质基质细胞的物质组成、制造方法和适应症。这些已授予的专利和专利申请提供了商业保护，延续至至少 2044 年，覆盖所有主要市场。</p>
<p><strong>关于 Mesoblast 的制造：</strong> 公司的专有制造工艺可生产工业规模的、冷冻保存的、现成的细胞药物。这些细胞疗法具有明确的药品释放标准，计划在全球范围内为患者提供便捷的可用性。</p>
<p>Mesoblast 在澳大利亚、美国和新加坡设有办事处，并在澳大利亚证券交易所（MSB）和纳斯达克（MESO）上市。有关更多信息，请访问 www.mesoblast.com，LinkedIn: Mesoblast Limited 和 X: @Mesoblast</p>
<p><strong>参考文献/脚注</strong></p>
<ol>
<li>TEMCELL® HS Inj.是 JCR Pharmaceuticals Co. Ltd.的注册商标。</li>
<li>基于 2025 年 12 月 29 日 RBA 发布的美元 - 澳元现货汇率 0.6722</li>
</ol>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含与未来事件或我们未来财务表现相关的前瞻性声明，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。我们根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的安全港条款作出此类前瞻性声明。前瞻性声明不应被视为对未来表现或结果的保证，实际结果可能与这些前瞻性声明中预期的结果不同，而这种差异可能是重大且不利的。前瞻性声明包括但不限于关于：Mesoblast 的临床前和临床研究的启动、时间、进展和结果，以及 Mesoblast 的研究和开发项目；Mesoblast 将产品候选者推进、招募并成功完成临床研究（包括跨国临床试验）的能力；Mesoblast 提升其制造能力的能力；监管申请和批准、制造活动和产品营销活动的时间或可能性（如有）；Mesoblast 的 RYONCIL 用于儿童 SR-aGVHD 及任何其他产品候选者（如获批准）的商业化；围绕干细胞治疗的监管或公众认知及市场接受度；如果有产品候选者获批准，因患者不良事件或死亡而可能被撤回市场的风险；战略合作协议的潜在利益及 Mesoblast 进入和维持已建立的战略合作的能力；Mesoblast 在其产品候选者上建立和维护知识产权的能力，以及在涉嫌侵权的情况下成功捍卫这些权利的能力；Mesoblast 能够为其产品候选者和技术建立和维护的知识产权保护范围；Mesoblast 的费用、未来收入、资本需求及其对额外融资的需求的估计；Mesoblast 的财务表现；与 Mesoblast 的竞争对手和行业相关的发展；以及 Mesoblast 的产品候选者（如获批准）的定价和报销情况。您应将本新闻稿与我们最近提交给 SEC 的报告或我们网站上的风险因素一起阅读。可能导致 Mesoblast 的实际结果、表现或成就与这些声明所表达或暗示的存在重大差异的不确定性和风险，因此，您不应对这些前瞻性声明过于依赖。我们不承担任何公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
<p>发布经首席执行官授权。</p>
<p><em>如需更多信息，请联系：</em></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><em>企业传播 / 投资者</em></strong></td>
<td></td>
</tr>
<tr>
<td>Paul Hughes</td>
<td></td>
</tr>
<tr>
<td>T: +61 3 9639 6036</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>媒体 – 全球</em></strong></td>
<td><strong><em>媒体 – 澳大利亚</em></strong></td>
</tr>
<tr>
<td>Allison Worldwide</td>
<td>BlueDot Media</td>
</tr>
<tr>
<td>Emma Neal</td>
<td>Steve Dabkowski</td>
</tr>
<tr>
<td>T: +1 603 545 4843</td>
<td>T: +61 419 880 486</td>
</tr>
<tr>
<td>E: emma.neal@allisonworldwide.com</td>
<td>E: steve@bluedot.net.au</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQXlNQ00zTXpNNU1UTXlJekl3TVRjME16ST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQXlNQ00zTXpNNU1UTXlJekl3TVRjME16ST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NzdkNjJiMjUtMTMxMS00YjYzLTkwZDUtMjQ4MTljNTkwYWZmLTEwMjkwMDUtMjAyNS0xMi0yOS1lbg==/tiny/Mesoblast-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NzdkNjJiMjUtMTMxMS00YjYzLTkwZDUtMjQ4MTljNTkwYWZmLTEwMjkwMDUtMjAyNS0xMi0yOS1lbg==/tiny/Mesoblast-Limited.png"/></p>

MESO

<p>Mesoblast Limited 已全额偿还其高级担保贷款，并通过从新的五年信用额度中提取 7500 万美元部分偿还其次级特许权使用费融资。该融资由 Dr. Gregory George 提供，总额为 1.25 亿美元，固定年利率为 8.00%，显著降低了公司的资本成本。新的信用额度在 NovaQuest 债务偿还之前是无担保的，并且不对任何重要资产或知识产权设定负担。Mesoblast 旨在利用这一灵活性进行战略合作和商业化</p>

<p><em>Mesoblast has option to draw down up to US$125 million by June 30, 2026</em></p>
<div class="lb-trans"><p><em>Mesoblast 有权在 2026 年 6 月 30 日前提取高达 1.25 亿美元</em></p>
</div><p><em>New facility does not encumber any of Mesoblast's material assets or intellectual property</em></p>
<div class="lb-trans"><p><em>新融资不会影响 Mesoblast 的任何重要资产或知识产权</em></p>
</div><p>NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has repaid in full its existing senior secured loan from Oaktree Capital Management, Inc. and in part its subordinated royalty facility from NovaQuest Capital Management LLC by drawing down US$75 million from a new five-year facility provided by existing Mesoblast shareholder and director Dr Gregory George. A second tranche of up to US$50 million is available to be drawn at Mesoblast’s option until June 30, 2026.</p>
<div class="lb-trans"><p>纽约，2025 年 12 月 29 日（GLOBE NEWSWIRE）-- Mesoblast Limited（纳斯达克：MESO；ASX：MSB），全球领先的用于治疗炎症疾病的同种异体细胞药物公司，今天宣布已全额偿还 Oaktree Capital Management, Inc.的现有高级担保贷款，并部分偿还 NovaQuest Capital Management LLC 的次级特许权使用费融资，通过从现有 Mesoblast 股东和董事 Dr. Gregory George 提供的新五年融资中提取 7500 万美元。第二笔高达 5000 万美元的融资可在 Mesoblast 的选择下，直到 2026 年 6 月 30 日提取。</p>
</div><p>The new credit-line has a fixed interest rate of 8.00% per annum, a substantial reduction from Mesoblast's current debt facilities, with a five-year interest only period. The initial US$75 million drawn is unsecured until the remainder of the NovaQuest debt is repaid, no later than July 8, 2026, after which the entire new facility (up to US$125 million) will be secured solely with the Temcell1 royalty.</p>
<div class="lb-trans"><p>新的信用额度年利率为 8.00%，相比 Mesoblast 当前的债务融资大幅降低，且有五年的仅付息期。最初提取的 7500 万美元在 NovaQuest 债务偿还之前是无担保的，最晚在 2026 年 7 月 8 日偿还后，整个新融资（最高可达 1.25 亿美元）将仅以 Temcell1 特许权使用费作为担保。</p>
</div><p>The new facility has a substantially lower overall cost compared with existing facilities, can be repaid at any time without incurring early prepayment or make-whole fees, does not include exit fees, does not encumber any of Mesoblast's material assets or intellectual property, and has no restrictions on additional unsecured debt or licensing activities. Dr. George will receive 5-year warrants to purchase approximately 323,000 American Depositary Shares (ADSs) at US$21.51 per ADS2, a 15% premium to the current 30-day VWAP, subject to shareholder approval.</p>
<div class="lb-trans"><p>与现有融资相比，新融资的整体成本大幅降低，可以随时偿还而不产生提前还款或补偿费用，不包括退出费用，不影响 Mesoblast 的任何重要资产或知识产权，并且对额外的无担保债务或许可活动没有限制。Dr. George 将获得五年期的认股权证，可以以每股 21.51 美元的价格购买约 323,000 股美国存托股票（ADS），该价格比当前 30 天的加权平均价高出 15%，需经股东批准。</p>
</div><p>Mesoblast Chief Executive Dr. Silviu Itescu said &#34;We greatly appreciate the support of our largest shareholder who provided the most commercially compelling facility in a competitive process run over the course of this year. This facility substantially lowers the company’s cost of capital and frees up all of our major assets to provide total flexibility for strategic partnerships and commercialization.&#34;</p>
<div class="lb-trans"><p>Mesoblast 首席执行官 Dr. Silviu Itescu 表示：“我们非常感谢我们最大的股东在今年的竞争过程中提供了最具商业吸引力的融资。这项融资大幅降低了公司的资本成本，并释放了我们所有主要资产，为战略合作伙伴关系和商业化提供了完全的灵活性。”</p>
</div><p><strong>About Mesoblast</strong></p>
<div class="lb-trans"><p><strong>关于 Mesoblast</strong></p>
</div><p>Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.</p>
<div class="lb-trans"><p>Mesoblast（公司）是开发同种异体（现成）细胞药物以治疗严重和危及生命的炎症疾病的全球领导者。公司专有的间充质谱系细胞治疗技术平台的疗法通过释放抗炎因子来应对严重炎症，抵消和调节免疫系统的多个效应臂，从而显著减少有害的炎症过程。</p>
</div><p>Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.</p>
<div class="lb-trans"><p>Mesoblast 的 Ryoncil®（remestemcel-L-rknd）用于治疗 2 个月及以上儿童患者的类固醇难治性急性移植物抗宿主病（SR-aGvHD），是 FDA 批准的首个间充质基质细胞（MSC）疗法。请参阅完整的处方信息，网址为 www.ryoncil.com。</p>
</div><p>Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.</p>
<div class="lb-trans"><p>Mesoblast 致力于基于其 remestemcel-L 和 rexlemestrocel-L 同种异体基质细胞技术平台开发针对不同适应症的额外细胞疗法。Ryoncil®正在开发用于包括成人 SR-aGvHD 和生物抵抗性炎症性肠病在内的其他炎症疾病。Rexlemestrocel-L 正在开发用于心力衰竭和慢性下背痛。公司已在日本、欧洲和中国建立了商业合作伙伴关系。</p>
</div><p><strong>About Mesoblast intellectual property:</strong> Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.</p>
<div class="lb-trans"><p><strong>关于 Mesoblast 的知识产权：</strong> Mesoblast 拥有强大而广泛的全球知识产权组合，拥有超过 1000 项已授予的专利或专利申请，涵盖间充质基质细胞的物质组成、制造方法和适应症。这些已授予的专利和专利申请提供了商业保护，延续至至少 2044 年，覆盖所有主要市场。</p>
</div><p><strong>About Mesoblast manufacturing:</strong> The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.</p>
<div class="lb-trans"><p><strong>关于 Mesoblast 的制造：</strong> 公司的专有制造工艺可生产工业规模的、冷冻保存的、现成的细胞药物。这些细胞疗法具有明确的药品释放标准，计划在全球范围内为患者提供便捷的可用性。</p>
</div><p>Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast</p>
<div class="lb-trans"><p>Mesoblast 在澳大利亚、美国和新加坡设有办事处，并在澳大利亚证券交易所（MSB）和纳斯达克（MESO）上市。有关更多信息，请访问 www.mesoblast.com，LinkedIn: Mesoblast Limited 和 X: @Mesoblast</p>
</div><p><strong>References / Footnotes</strong></p>
<div class="lb-trans"><p><strong>参考文献/脚注</strong></p>
</div><ol>
<li>TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd.</li>
<li>Based on USD-AUD 0.6722 spot rate published by RBA at Dec 29, 2025</li>
</ol>
<div class="lb-trans"><ol>
<li>TEMCELL® HS Inj.是 JCR Pharmaceuticals Co. Ltd.的注册商标。</li>
<li>基于 2025 年 12 月 29 日 RBA 发布的美元 - 澳元现货汇率 0.6722</li>
</ol>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含与未来事件或我们未来财务表现相关的前瞻性声明，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。我们根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的安全港条款作出此类前瞻性声明。前瞻性声明不应被视为对未来表现或结果的保证，实际结果可能与这些前瞻性声明中预期的结果不同，而这种差异可能是重大且不利的。前瞻性声明包括但不限于关于：Mesoblast 的临床前和临床研究的启动、时间、进展和结果，以及 Mesoblast 的研究和开发项目；Mesoblast 将产品候选者推进、招募并成功完成临床研究（包括跨国临床试验）的能力；Mesoblast 提升其制造能力的能力；监管申请和批准、制造活动和产品营销活动的时间或可能性（如有）；Mesoblast 的 RYONCIL 用于儿童 SR-aGVHD 及任何其他产品候选者（如获批准）的商业化；围绕干细胞治疗的监管或公众认知及市场接受度；如果有产品候选者获批准，因患者不良事件或死亡而可能被撤回市场的风险；战略合作协议的潜在利益及 Mesoblast 进入和维持已建立的战略合作的能力；Mesoblast 在其产品候选者上建立和维护知识产权的能力，以及在涉嫌侵权的情况下成功捍卫这些权利的能力；Mesoblast 能够为其产品候选者和技术建立和维护的知识产权保护范围；Mesoblast 的费用、未来收入、资本需求及其对额外融资的需求的估计；Mesoblast 的财务表现；与 Mesoblast 的竞争对手和行业相关的发展；以及 Mesoblast 的产品候选者（如获批准）的定价和报销情况。您应将本新闻稿与我们最近提交给 SEC 的报告或我们网站上的风险因素一起阅读。可能导致 Mesoblast 的实际结果、表现或成就与这些声明所表达或暗示的存在重大差异的不确定性和风险，因此，您不应对这些前瞻性声明过于依赖。我们不承担任何公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
</div><p>Release authorized by the Chief Executive.</p>
<div class="lb-trans"><p>发布经首席执行官授权。</p>
</div><p><em>For more information, please contact:</em></p>
<div class="lb-trans"><p><em>如需更多信息，请联系：</em></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><em>Corporate Communications / Investors</em></strong></td>
<td></td>
</tr>
<tr>
<td>Paul Hughes</td>
<td></td>
</tr>
<tr>
<td>T: +61 3 9639 6036</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>Media – Global</em></strong></td>
<td><strong><em>Media – Australia</em></strong></td>
</tr>
<tr>
<td>Allison Worldwide</td>
<td>BlueDot Media</td>
</tr>
<tr>
<td>Emma Neal</td>
<td>Steve Dabkowski</td>
</tr>
<tr>
<td>T: +1 603 545 4843</td>
<td>T: +61 419 880 486</td>
</tr>
<tr>
<td>E: emma.neal@allisonworldwide.com</td>
<td>E: steve@bluedot.net.au</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><em>企业传播 / 投资者</em></strong></td>
<td></td>
</tr>
<tr>
<td>Paul Hughes</td>
<td></td>
</tr>
<tr>
<td>T: +61 3 9639 6036</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>媒体 – 全球</em></strong></td>
<td><strong><em>媒体 – 澳大利亚</em></strong></td>
</tr>
<tr>
<td>Allison Worldwide</td>
<td>BlueDot Media</td>
</tr>
<tr>
<td>Emma Neal</td>
<td>Steve Dabkowski</td>
</tr>
<tr>
<td>T: +1 603 545 4843</td>
<td>T: +61 419 880 486</td>
</tr>
<tr>
<td>E: emma.neal@allisonworldwide.com</td>
<td>E: steve@bluedot.net.au</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQXlNQ00zTXpNNU1UTXlJekl3TVRjME16ST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODAyMCM3MzM5MTMyIzIwMTc0MzI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NzdkNjJiMjUtMTMxMS00YjYzLTkwZDUtMjQ4MTljNTkwYWZmLTEwMjkwMDUtMjAyNS0xMi0yOS1lbg==/tiny/Mesoblast-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/NzdkNjJiMjUtMTMxMS00YjYzLTkwZDUtMjQ4MTljNTkwYWZmLTEwMjkwMDUtMjAyNS0xMi0yOS1lbg==/tiny/Mesoblast-Limited.png"/></p>

Mesoblast 通过无稀释、成本更低的五年期信贷额度偿还了高级债务 | MESO 股票新闻